Compare Global X Lithium & Battery Tech ETF (LIT) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Lithium & Battery Tech ETF vs Novartis AG — how do they compare? Global X Lithium & Battery Tech ETF trades at $69.73 (market cap $1.45B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 185.2× Global X Lithium & Battery Tech ETF's market cap, and Novartis AG pays a 3.31% dividend while Global X Lithium & Battery Tech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Lithium & Battery Tech ETF for 56 Days and Novartis AG for 82 Days on average.
| LIT | NVS | |
|---|---|---|
Market Cap | $1.45B | $268.57B |
Volume | 89,392 | 1,532,573 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $91.62 | $168.62 |
52-Week Low | $53.92 | $121.80 |
Typical Hold Time | 56 Days | 82 Days |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LIT trades at $69.73, up 0.32% with mixed technical signals showing a bullish overall trend but bearish moving averages and oscillators. The ETF's price action remains volatile, trading near key support/resistance levels. Recent news highlights significant short interest reduction and ongoing exposure to the lithium and battery technology sector, which faces both supply chain challenges and long-term growth potential from electric vehicle adoption.
The outlook for LIT is cautiously optimistic, driven by global EV adoption trends and energy storage demand, though tempered by lithium price volatility and competitive pressures. Key risks include commodity price swings and geopolitical factors affecting battery supply chains, while institutional sentiment shows mixed signals with technical indicators suggesting near-term consolidation.
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
